Navigating Cosmetic Dermatology in Pregnancy and Lactation: Evidence-Based Safety Guidelines

Cosmetic dermatologic care during pregnancy and lactation presents a common clinical challenge: patients may seek treatment for skin changes while clinicians must balance aesthetic goals with limited reproductive safety data. A new narrative review synthesized available evidence for topical agents, chemical peels, injectables, lasers and light-based therapies, and energy-based devices and proposes a practical framework for counseling. The research emphasizes that pregnancy and lactation should not be treated as equivalent clinical states.¹

Physiologic Changes and the Argument for Conservative Care

In an analysis of 62 published studies, investigators found that many cosmetic concerns arising during pregnancy are physiologic and may improve after delivery. Hormonal changes can contribute to melasma, linea nigra, and changes in nevi and ephelides, while connective tissue remodeling can result in striae gravidarum. Increased vascularity may produce flushing, telangiectasias, spider angiomas, and palmar erythema. Edema and increased vascularity may also increase bruising and inflammatory responses following procedures. Pregnancy-related hair and nail changes and benign growths such as acrochordons may likewise improve postpartum. These factors support conservative management and reassessment after delivery before pursuing elective procedures.

MORE ON AESTHETICS

Safety Considerations for Topicals and Chemical Peels

For topical products, the review distinguishes between agents according to expected systemic exposure and available safety evidence. Vitamin C, azelaic acid, niacinamide, and benzoyl peroxide are considered acceptable during pregnancy and lactation. Low-concentration glycolic or lactic acid products may be used with caution during pregnancy. Hydroquinone is recommended to be avoided because of relatively high systemic absorption and limited reproductive safety data. Topical tretinoin and adapalene are also avoided during pregnancy despite observational studies not consistently demonstrating increased congenital malformations; the recommendation is based on the retinoid class effect and availability of safer alternatives. Tazarotene and oral minoxidil are avoided during both pregnancy and lactation, while topical minoxidil may be considered with caution during lactation.

Chemical peels generally warrant greater caution because higher concentrations and treatment conditions can increase systemic absorption. Superficial glycolic and lactic acid peels have the most favorable profiles but are preferably deferred for elective cosmetic use during pregnancy. Salicylic acid peels are avoided during pregnancy, particularly when higher concentrations or conditions that increase absorption are involved. Medium-depth trichloroacetic acid peels are deferred because reproductive safety data are lacking, while deep phenol peels should be avoided during both pregnancy and lactation because phenol has documented systemic toxicity, including cardiac arrhythmias.

Injectables, Energy-Based Devices, Lasers, and Resurfacing Procedures

Injectable cosmetic procedures are generally avoided or deferred during pregnancy because prospective safety data are lacking. Although inadvertent exposure data for botulinum toxin have not shown a clear increase in adverse pregnancy outcomes, the review notes that these findings cannot necessarily be extrapolated to elective cosmetic treatment. During lactation, botulinum toxin may be considered with caution, while hyaluronic acid fillers may also be considered after individualized assessment. Deoxycholic acid, mesotherapy, and sclerotherapy are avoided or deferred because of limited safety information and procedural concerns.

MORE FROM NP/PA CONNECT

Similarly, elective lasers and light-based procedures are generally deferred during pregnancy because of limited pregnancy-specific data and potential changes in healing, pigmentation, vascularity, and tissue response. Selected procedures may be considered during lactation when systemic exposure is negligible and direct infant exposure is avoided. Microdermabrasion is considered acceptable during both pregnancy and lactation, while microneedling is deferred during pregnancy but may be acceptable during lactation.

Clinical Decision-Making Framework

The review ultimately recommends a patient-centered approach: determine whether treatment is cosmetic or medically necessary, establish whether the patient is pregnant or lactating, assess systemic exposure and treatment location, consider postpartum reversibility, and discuss evidence limitations.

“Until more robust data become available, clinicians should prioritize conservative management, patient education, and shared decision-making to guide cosmetic treatment decisions in this unique population,” the authors wrote.

Reference

1. Kovacs T, Nadir U, Goldenberg M, et al. Cosmetic Dermatology in Pregnancy and Lactation: A Risk-Benefit Framework for Clinical Practice. Int J Dermatol. Published online August 24, 2026. doi:10.1111/ijd.70620